NCT03643510View on ClinicalTrials.gov

Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 21, 2018

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Adenocarcinoma of Endometrium
Interventions
DRUG

Fulvestrant

Fulvestrant will be dosed 500mg intramuscularly (IM) on days 1 and 15 during cycle 1 and then on Day 1 during subsequent cycles.

DRUG

Abemaciclib

Abemaciclib 150 milligrams mg orally once every 12 hours on days 1-28.

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Commack, Commack

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT03643510 - Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer | Biotech Hunter | Biotech Hunter